Entera Bio (NASDAQ:ENTX) Stock Rating Upgraded by Wall Street Zen

Entera Bio (NASDAQ:ENTX) was upgraded by research analysts at Wall Street Zen to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Entera Bio has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Entera Bio Stock Performance

Shares of NASDAQ ENTX opened at $1.72 on Friday. The company’s fifty day moving average is $2.39 and its two-hundred day moving average is $2.12. The firm has a market capitalization of $78.88 million, a P/E ratio of -6.88 and a beta of 1.71. Entera Bio has a one year low of $1.50 and a one year high of $3.22.

Entera Bio (NASDAQ:ENTX) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.02. Entera Bio had a negative net margin of 4,525.11% and a negative return on equity of 67.56%. On average, sell-side analysts forecast that Entera Bio will post -0.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Entera Bio

A number of institutional investors have recently made changes to their positions in the stock. HighTower Advisors LLC increased its position in Entera Bio by 53.3% during the 1st quarter. HighTower Advisors LLC now owns 18,140 shares of the company’s stock worth $31,000 after purchasing an additional 6,310 shares in the last quarter. Citadel Advisors LLC boosted its stake in shares of Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after purchasing an additional 28,322 shares during the last quarter. Bessemer Group Inc. purchased a new stake in shares of Entera Bio during the second quarter worth about $268,000. Finally, Parkman Healthcare Partners LLC raised its position in shares of Entera Bio by 6.3% in the first quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company’s stock valued at $747,000 after buying an additional 25,900 shares during the last quarter. 14.11% of the stock is owned by institutional investors and hedge funds.

About Entera Bio

Entera Bio, Inc is a clinical?stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.